TherapeuticsMD, Inc. (TXMD)
↓ Download CSV- Sector Manufacturing
- Incorporated NV
- Fiscal year ends Dec 31
In fiscal 2025, TherapeuticsMD, Inc. reported revenue of $3.02M, up 71.6% from the prior year. The company ran a net loss, with a net margin of -18.8%. It held $37.66M in total assets against $10.78M in total liabilities.
Key ratios (FY2025)
-145.3%
Operating margin
-18.8%
Net margin
-2.1%
Return on equity
+71.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.02M | $1.76M | $1.30M | $69.96M | $2.57M | $64.87M | $49.65M | — | — | — |
| Cost of Revenue | — | — | — | $1.40M | $1.40M | $15.97M | $6.33M | $2.74M | $2.64M | $4.19M |
| Gross Profit | — | — | $1.30M | $68.57M | $1.17M | $48.90M | $43.31M | $13.36M | $14.14M | $15.17M |
| Operating Income | -$4.39M | -$6.11M | -$8.52M | $1.19M | -$79.58M | -$155.54M | -$151.21M | -$130.22M | -$77.63M | -$90.25M |
| Net Income | -$569.0K | -$2.18M | -$10.28M | $112.00M | -$172.41M | -$183.52M | -$176.15M | -$132.62M | -$76.93M | -$89.88M |
| EPS (Diluted) | $-0.05 | $-0.19 | $-0.99 | $11.96 | $-21.66 | — | — | — | — | — |
| Total Assets | $37.66M | $38.82M | $43.31M | $90.46M | $169.47M | $181.61M | $265.99M | $211.98M | $143.23M | $142.47M |
| Total Liabilities | $10.78M | $11.45M | $14.02M | $55.31M | $263.09M | $305.61M | $256.78M | $114.46M | $13.32M | — |
| Shareholders' Equity | $26.88M | $27.37M | $29.29M | $35.14M | -$93.62M | -$124.00M | $9.20M | $97.52M | $129.91M | $127.49M |
| Cash & Equivalents | — | $5.06M | $4.33M | — | — | — | — | — | — | — |
| Operating Cash Flow | $2.45M | $1.17M | -$23.08M | $9.36M | -$55.13M | — | — | — | — | — |
| Capital Expenditures | — | — | — | — | $34.0K | $207.0K | $2.45M | $217.0K | $61.8K | $396.2K |
| Shares Outstanding | 11.57M | 11.53M | 11.53M | 9.50M | 8.60M | 299.76M | 271.18M | 240.46M | 216.43M | 196.69M |